Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On March 31, 2023, we reported on a study published in JAMA Psychiatry that examined the association of receipt of telehealth services and medications for opioid use disorder (OUD) with fatal drug overdoses before and during the COVID-19 pandemic.
The study
Investigators compared data from 2 cohorts of Medicare beneficiaries aged ≥18 years with OUD across 2 time periods. The first cohort (prepandemic cohort) was constructed with data from September 2018-February 2020 and included 105 162 beneficiaries (58.1% women, 67.6% aged 45-74 years). The second cohort (pandemic cohort) was constructed with data from September 2019-February 2021 and included 70 479 beneficiaries (57.1% women, 66.3% aged 45-74 years). Also, the researchers conducted an analysis to examine the demographic and clinical characteristics associated with fatal overdose in the pandemic cohort.
A larger percentage of persons in the pandemic cohort received OUD-related telehealth services than those in the prepandemic cohort (13 809 [19.6%] vs 590 [0.6%]; P<.001). Receipt of medications for OUD (MOUD) was higher in the pandemic cohort than in the prepandemic cohort (8826 [12.6%] vs 11 304 [10.8%]; P<.001). Researchers observed a higher rate of all-cause mortality in the pandemic cohort (99.9 per 1000 beneficiaries; 7041 deaths) than in the prepandemic cohort (76.8 per 1000 beneficiaries; 8076 deaths) (P<.001). The rate of fatal drug overdoses was also higher in the pandemic cohort (5.1 per 1000 beneficiaries; n=358) than in the prepandemic cohort (3.7 per 1000 beneficiaries; n=391) (P<.001). The percentage of deaths due to a fatal drug overdose was similar in the prepandemic cohort (4.8%) and pandemic (5.1%) cohort (P=.49).
Note from authors
"This cohort study found that, among Medicare beneficiaries initiating OUD-related care during the COVID-19 pandemic, receipt of OUD-related telehealth services was associated with reduced risk for fatal drug overdose, as was receipt of MOUD from opioid treatment programs and receipt of buprenorphine in office-based settings. Strategies to expand provision of MOUD, increase retention in care, and address co-occurring physical and behavioral health conditions are needed."
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.